Comparative Pharmacology
Head-to-head clinical analysis: PHOSLO GELCAPS versus PHOSLYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLO GELCAPS versus PHOSLYRA.
PHOSLO GELCAPS vs PHOSLYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium acetate binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in feces, thereby reducing serum phosphate levels.
Phoslyra (calcium acetate) binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in the feces, thereby reducing serum phosphate levels.
Oral: One to two capsules (668-1336 mg calcium acetate) three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL, maximum 4 capsules per meal.
1330 mg (one caplet) orally three times daily with meals, titrated to achieve serum phosphorus within target range.
None Documented
None Documented
Not applicable; calcium is a physiologic ion with dynamic regulation; steady-state serum calcium is maintained by homeostatic mechanisms. In overdose, serum calcium half-life is approximately 3-4 hours.
Not applicable; Phoslyra (calcium acetate) is not absorbed systemically; local effect in GI tract.
Primarily fecal as unabsorbed calcium; renal excretion accounts for <1% of absorbed dose proportional to glomerular filtration rate.
Renal 100% as unchanged drug, no biliary or fecal elimination.
Category C
Category C
Phosphate Binder
Phosphate Binder